Heparin scare may prompt law
This article was originally published in The Tan Sheet
Executive Summary
The House Committee on Energy and Commerce may propose "emergency legislation" requiring FDA to inspect and approve drug manufacturers before they ship products to the U.S., according to letters sent Feb. 21 to FDA and the Health and Human Services Department by Chairman John Dingell and Rep. Bart Stupak, Subcommittee on Oversight and Investigations chairman. The Michigan Democrats are investigating whether such legislation is necessary "to protect Americans" following FDA's failure to inspect a Chinese manufacturer that may be connected to the roughly 350 adverse events and four deaths related to Baxter Healthcare's injectable blood thinner Heparin (1"The Tan Sheet" Feb. 18, 2008, p. 15). The chairmen lambaste FDA, alleging the agency "abandoned ... its vital pre-approval inspection policy for the U.S. drug supply." In addition, they ask FDA, HHS and Baxter to turn over records related to the Heparin scare for further review...
You may also be interested in...
Heparin personal injury suit
A personal injury lawsuit was filed against Camden, N.J.-based Baxter Healthcare in federal court in New Jersey, according to New York-based law firm Lieff Cabraser Heimann & Bernstein. The plaintiff in the law suit claims to have suffered a near fatal adverse reaction from Baxter's contaminated heparin prescription blood thinner. The complaint seeks damages for physical pain and medical expenses, along with punitive damages to prevent Baxter from "similar wrongdoing in the future," according to the firm's April 3 release. Baxter came under fire after its failure to inspect a Chinese manufacturer that was the source of an ingredient used in heparin products that may be connected with hundreds of adverse events and four deaths (1"The Tan Sheet" Feb. 25, 2008, In Brief)...
FDA Template Good For Firms’ Recall Announcements – Consultant
FDA should request that firms use a proposed template for the agency's recall announcements to communicate their recalls to the public, a consultant said at the first meeting of the Risk Communications Advisory Committee
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.